Immune globulin (OMRIX Viopharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameImmune globulin (OMRIX Viopharmaceuticals)

Drug Alias NameIntravenous immunoglobulin (Omrix)Immune deficiency immune globulin therapy (Omrix)Immunoglobulin intravenous (Omrix)Omr-IgG-am-IVIGOmr-IgG-am

ClassificationBiologics > Blood componentsBiologics > Protein drugs > Immunoglobulin

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsImmunologic Deficiency SyndromesAutoimmune DiseasesWest Nile Fever

Global Approved IndicationsImmunologic Deficiency SyndromesAutoimmune Diseases

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIsrael

Original Approved Date2006/01/01

Country/TerritoryCanadaUnited StatesIsrael

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesOmrix Biopharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesOmrix Biopharmaceuticals

Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)National Institute Of Allergy And Infectious Diseases (Niaid)

Active IndicationsImmunologic Deficiency SyndromesAutoimmune Diseases

Inactive IndicationsWest Nile Fever

Other Information

ATC CodeJ06BA02